{"filing":{"accession_number":"0001193125-26-301464","cik":"0001661998","ticker":"QTTB","company_name":"Q32 Bio Inc.","form":"8-K","filing_date":"2026-07-13","report_date":null,"primary_document":"d142528d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1661998/000119312526301464/d142528d8k.htm"},"events":[{"id":17458,"run_id":15632,"accession_number":"0001193125-26-301464","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Q32 Bio announced positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial of bempikibart in alopecia areata, demonstrating clinically meaningful efficacy (35.3% mean reduction in SALT score, 40% SALT-20 response rate) and a well-tolerated safety profile with no new safety signals, supporting advancement into a registration-directed program in H1 2027.","company_name":"Q32 Bio Inc.","ticker":"QTTB","filing_date":"2026-07-13","form":"8-K","submitted_at":null,"items":[{"id":15938,"accession_number":"0001193125-26-301464","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"Q32 Bio announced positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial of bempikibart in alopecia areata, including clinically meaningful efficacy data (35.3% mean reduction in SALT score), favorable safety profile, and plans to advance into a registration-directed program in H1 2027. This is a material clinical development milestone for a clinical-stage biotech company, but does not fit the earnings_release category (which typically applies to financial results) nor any other specific taxonomy type. The disclosure centers on a significant operational/clinical advancement rather than financial results, M\u0026A, governance, or other named event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T11:13:14.967706+00:00","company_name":"","ticker":null,"filing_date":""},{"id":15939,"accession_number":"0001193125-26-301464","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Q32 Bio announced positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial of bempikibart in alopecia areata, demonstrating clinically meaningful efficacy (35.3% mean reduction in SALT score, 40% SALT-20 response rate) and a well-tolerated safety profile with no new safety signals. This is a material clinical development milestone for a clinical-stage biotech company that supports advancement into a registration-directed program in H1 2027, making it a significant operational/strategic event rather than a routine earnings release or other category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T11:13:14.967706+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":15938,"accession_number":"0001193125-26-301464","item_number":"7.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.72,"reasoning":"Q32 Bio announced positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial of bempikibart in alopecia areata, including clinically meaningful efficacy data (35.3% mean reduction in SALT score), favorable safety profile, and plans to advance into a registration-directed program in H1 2027. This is a material clinical development milestone for a clinical-stage biotech company, but does not fit the earnings_release category (which typically applies to financial results) nor any other specific taxonomy type. The disclosure centers on a significant operational/clinical advancement rather than financial results, M\u0026A, governance, or other named event types.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T11:13:14.967706+00:00","company_name":"Q32 Bio Inc.","ticker":"QTTB","filing_date":"2026-07-13"},{"id":15939,"accession_number":"0001193125-26-301464","item_number":"8.01","item_title":null,"event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Q32 Bio announced positive 36-week topline results from Part B of the SIGNAL-AA Phase 2a clinical trial of bempikibart in alopecia areata, demonstrating clinically meaningful efficacy (35.3% mean reduction in SALT score, 40% SALT-20 response rate) and a well-tolerated safety profile with no new safety signals. This is a material clinical development milestone for a clinical-stage biotech company that supports advancement into a registration-directed program in H1 2027, making it a significant operational/strategic event rather than a routine earnings release or other category.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-13T11:13:14.967706+00:00","company_name":"Q32 Bio Inc.","ticker":"QTTB","filing_date":"2026-07-13"}]}